https://commons.ru.ac.za/vital/access/manager/Index ${session.getAttribute("locale")} 5 https://commons.ru.ac.za/vital/access/manager/Repository/vital:50038 Wed 20 Apr 2022 08:42:45 SAST ]]> https://commons.ru.ac.za/vital/access/manager/Repository/vital:26603 0.9. The release mechanism was confirmed using the Korsmeyer-Peppas model that revealed that most of the formulations exhibited anomalous transport kinetics with the release exponent, n, ranging from 0.5 Wed 12 May 2021 23:42:25 SAST ]]> https://commons.ru.ac.za/vital/access/manager/Repository/vital:28349 Wed 12 May 2021 23:17:40 SAST ]]> https://commons.ru.ac.za/vital/access/manager/Repository/vital:28422 Wed 12 May 2021 21:00:47 SAST ]]> https://commons.ru.ac.za/vital/access/manager/Repository/vital:37893 Wed 12 May 2021 20:10:00 SAST ]]> https://commons.ru.ac.za/vital/access/manager/Repository/vital:28405 Wed 12 May 2021 17:20:09 SAST ]]> https://commons.ru.ac.za/vital/access/manager/Repository/vital:34583 Wed 12 May 2021 15:54:57 SAST ]]> https://commons.ru.ac.za/vital/access/manager/Repository/vital:41116 Wed 12 May 2021 14:04:29 SAST ]]> https://commons.ru.ac.za/vital/access/manager/Repository/vital:41158 Wed 12 May 2021 13:57:45 SAST ]]> https://commons.ru.ac.za/vital/access/manager/Repository/vital:45225 Tue 16 Nov 2021 13:35:29 SAST ]]> https://commons.ru.ac.za/vital/access/manager/Repository/vital:45223 Tue 16 Nov 2021 13:34:06 SAST ]]> https://commons.ru.ac.za/vital/access/manager/Repository/vital:45222 Tue 16 Nov 2021 13:33:18 SAST ]]> https://commons.ru.ac.za/vital/access/manager/Repository/vital:28701 Tue 10 Jul 2018 16:05:19 SAST ]]> https://commons.ru.ac.za/vital/access/manager/Repository/vital:27441 Thu 13 May 2021 07:08:53 SAST ]]> https://commons.ru.ac.za/vital/access/manager/Repository/vital:28419 Thu 13 May 2021 03:17:54 SAST ]]> https://commons.ru.ac.za/vital/access/manager/Repository/vital:28223 Thu 13 May 2021 02:15:56 SAST ]]> https://commons.ru.ac.za/vital/access/manager/Repository/vital:45247 Mon 15 Nov 2021 11:36:45 SAST ]]> https://commons.ru.ac.za/vital/access/manager/Repository/vital:42109 80%. The formulation composition identified was subsequently used for the optimization of the manufacturing parameters viz. sonication time and amplitude, using a Central Composite Design (CCD) . The LC and EE, in vitro CLA release, cytotoxicity, osmolarity, pH, degree of crystallinity and lipid modification, elemental analysis and surface morphology of the optimized batch was investigated and mon itored to ensure that CLA - loaded NLC, of the desirable quality, had been produced. On the day of manufacture the mean PS and PDI of the optimized CLA - loaded NLC formulation adjusted to physiological osmolarity (250 – 450 mOsm/kg) was 461.9 ± 40.16 nm and 0. 523 ± 0.104, respectively. The ZP for the optimized NLC generated on the day of manufacture using HPLC grade water as the dispersion medium was - 20.5 ± 4.82 mV. The pH and osmolarity of the optimized CLA - loaded NLC formulation was 7.76 ± 0.01 and 316 ± iii 2 m Osm/Kg, respectively and the EE was 88.62 ± 0.23 %. The optimized NLC exhibited a decreased crystallinity in comparison to the bulk lipid materials. DSC, WAXS and FT - IR revealed that CLA was molecularly dispersed in the nanocarriers. The optimized CLA - load ed NLC exhibited muco - adhesive properties, when tested under stationary conditions using laser doppler anemometry (LDA). The optimized formulation also exhibited sustained release of CLA over 24 hours during in vitro release testing and CLA release was bes t described using the Baker - Lonsdale model . The cumulative % CLA released over 24 hours was 56.13 ± 0.23% and mass balance analysis revealed 41.38 ± 0.02% CLA had been retained in the NLC. In vitro cytotoxicity testing revealed that the optimized CLA - NLC w ere less cytotoxic to HeLa cells when compared to CLA alone and further confirmed that the lipids and excipients used in these studies were of GRAS status . Stability studies revealed that the EE reduced over 28 days by 14.42% and 5.14% when stored at 4 °C and 22 °C , respectively. In addition, the particle size increased from the nm to μm range for samples stored at 22 °C. The findings are a good starting point but require further optimization to ensure prolongation of stability. In addition , the technology requires additional developmental studies and a powder for reconstitution for use as a single - dose considered as single dose packaging may be a solution to the compromised formulation stability observed in these studies. The CLA - NLC produced in these stu dies exhibit sound product attributes which serve as a useful foundation for the novel delivery of antibiotics to the eye. The results suggest that the optimized NLC have the potential to enhance precorneal retention and increase ocular availability of CLA , which in turn may be useful to reduce the required dose and dosing frequency when administering CLA as a reconstituted solution to treat susceptible organisms that infect ocular tissues.]]> Fri 06 Aug 2021 09:14:42 SAST ]]>